Melatonin as Adjunctive Therapy in the Prophylaxis of Cluster Headache: A Pilot Study

Tamara Pringsheim MD

Tamara Pringsheim MD

From the Department of Neurology and Neurosurgery, Montreal Neurological Institute, McGill University, Montreal, Canada

Search for more papers by this author
Eric Magnoux MD

Eric Magnoux MD

Montreal Migraine Clinic, Montreal, Canada

Search for more papers by this author
Colin F. Dobson BSc

Colin F. Dobson BSc

From the Department of Neurology and Neurosurgery, Montreal Neurological Institute, McGill University, Montreal, Canada

Search for more papers by this author
Edith Hamel PhD

Edith Hamel PhD

From the Department of Neurology and Neurosurgery, Montreal Neurological Institute, McGill University, Montreal, Canada

Search for more papers by this author
Michel Aubé MD

Michel Aubé MD

From the Department of Neurology and Neurosurgery, Montreal Neurological Institute, McGill University, Montreal, Canada

Search for more papers by this author
First published: 24 October 2002
Citations: 81
Dr. Tamara Pringsheim, c/o Dr. Michel Aubé, Montreal Neurological Institute, 3801 University Avenue, Room 138, Montreal, Quebec, Canada H2A 3B4.

Abstract

Background.—The periodicity of cluster headache suggests involvement of the suprachiasmatic nucleus of the hypothalamus, the biological clock. The secretion of melatonin, a hormone produced by the pineal gland and regulated by the suprachiasmatic nucleus, is altered in patients with cluster headache. Melatonin shifts circadian rhythms. A previous study of melatonin for primary prophylaxis of cluster headache demonstrated a 50% response rate.

Objective.—To evaluate the use of melatonin as adjunctive therapy in patients with cluster headache who have incomplete relief of their headaches on conventional therapy.

Methods.—Nine patients participated in the study, six with chronic cluster headache and three with episodic cluster headache. Patients with chronic cluster headache completed a baseline diary for 1 month, followed by 1 month of melatonin treatment, then 1 month of placebo. Patients with episodic cluster headache received placebo for 1 month, then melatonin for 1 month. Patients continued their usual prophylactic and abortive treatments during the study. Headache frequency, intensity, and use of analgesics were recorded. The primary endpoint of the study was the mean number of headaches per day, with mean daily analgesic consumption and percentage of mild, moderate, and severe headaches as secondary endpoints.

Results.—There were no significant differences between means on analysis of variance and t testing for the melatonin, placebo, and baseline months for all primary and secondary endpoints. There were no side effects reported.

Conclusions.—Patients with chronic cluster headache or patients with episodic cluster headache whose headaches are uncontrolled on conventional therapy do not appear to gain therapeutically from the addition of melatonin to their usual treatment regimens. It is perhaps the phase-shifting properties of melatonin that mediate its effect in patients with episodic cluster headache, and it may be necessary to treat from the beginning of the cluster bout to reset the circadian pacemaker, thus producing a more positive outcome.